Concepedia

Klaus Hinterding

KH

Statistics

Publications

12

Citations

1K

H-Index

12

Active since

1997

Affiliations

Novartis (Switzerland)(Current)

Karlsruhe Institute of Technology

Genomics Institute of the Novartis Research Foundation

Max Planck Society

Harvard University

Klaus Hinterding is an author at Novartis (Switzerland) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

1997–2013

12

Publications

12

The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rate

P Gergely, Barbara Nuesslein‐Hildesheim, Danilo Guerini et al. · British Journal of Pharmacology · 2012 · 304 citations · Full text

, , +15

Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator

Shifeng Pan, Nathanael S. Gray, Wenqi Gao et al. · ACS Medicinal Chemistry Letters · 2013 · 169 citations · Full text

, , +9

Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer

Rainer Albert, Klaus Hinterding, Volker Brinkmann et al. · Journal of Medicinal Chemistry · 2005 · 150 citations · Full text

, , +12

A Monoselective Sphingosine-1-Phosphate Receptor-1 Agonist Prevents Allograft Rejection in a Stringent Rat Heart Transplantation Model

Shifeng Pan, Yuan Mi, Charles Pally et al. · Chemistry & Biology · 2006 · 127 citations

, , +12

Regioselective Carbomethoxylation of Chiral Epoxides:  A New Route to Enantiomerically Pure β-Hydroxy Esters

Klaus Hinterding, Eric N. Jacobsen · The Journal of Organic Chemistry · 1999 · 71 citations

, , +6

1–5 of 12